BCG疫苗与麻风家庭接触者:保护效果及随访期间发病概率
共92人发病,其中41.3%在首年发病;首次评估有2个BCG瘢痕者额外保护效果显著(RR=0.41,p=0.007),且BCG瘢痕数影响生存曲线。
要点
- 首次评估有2个BCG瘢痕的接触者额外保护效果显著(RR=0.41,p=0.007)。
- 92例发病者中41.3%在随访第一年发病,62%为界线类偏结核样型。
- 0个BCG瘢痕者平均22个月发病,2个瘢痕者平均36个月,生存曲线差异显著。
核心结论
- BCG疫苗对已有2个瘢痕的麻风家庭接触者具有额外保护效果,可降低发病风险并延长生存时间。
- 减少麻风家庭接触者发病依赖于免疫预防和指示病例治疗等预防措施。
研究设计与样本
- 统计分析采用相对风险、风险比和Kaplan-Meier生存曲线。
主要发现
- 共92名接触者发病,其中41.3%(38/92)在随访第一年发病,58.7%(54/92)在其他年份发病。
- 发病者中62%(57/92)发展为界线类偏结核样型(BT)。
- 首次评估有2个BCG瘢痕者相比未暴露疫苗者,额外保护效果显著(RR=0.41;p=0.007)。
- BCG瘢痕数影响结局发生,生存曲线差异显著(Log Rank p=0.041;Breslow p=0.012;Tarone-Ware p=0.020)。
- 0个BCG瘢痕者平均发病时间22个月,2个瘢痕者平均36个月。
关键数值与推荐
- 首次评估有2个BCG瘢痕的接触者相对风险为0.41(p=0.007)。
- 生存曲线比较:Log Rank p=0.041,Breslow p=0.012,Tarone-Ware p=0.020。
- 0个BCG瘢痕者平均22个月发病,2个瘢痕者平均36个月发病。
临床怎么用
- 对无麻风症状和体征的健康家庭接触者接种BCG疫苗具有重要意义。
- 应结合BCG瘢痕数评估麻风家庭接触者的发病风险,并加强免疫预防和指示病例治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunoprophylaxis with Bacillus Calmette-Guérin (BCG) vaccine is still the most effective intervention in the prevention of leprosy among household contacts (HHCs) of leprosy patients. METHODS: A retrospective cohort study using data of 5.061 HHCs for a period of 16 years (follow-up of 7 years per leprosy HHCs), evaluating the occurrence of disease as the main outcome and the presence or absence of BCG scars verified at the first evaluation. Statistical analyzes were performed using the relative risk, hazard ratio and survival curves by Kaplan-Meier test. RESULTS: A total of 92 contacts sickened, of which 41.3% (38/92) in the first year and 58.7% (54/92) in the course of the other years of follow-up. Of those who became sick, 62% (57/92) developed borderline tuberculoid (BT). The additional protective effect occurred for those who had 2 BCG scars at the first follow-up assessment (Relative Risk: 0.41; p = 0.007) when compared to those not previously exposed to the vaccine. The number of BCG scars examined at the first assessment (t0 = time zero) affected the occurrence of the outcome evidenced by the difference in survival curves throughout the follow-up (Log Rank, p = 0.041; Breslow, p = 0.012; Tarone-Ware, p = 0.020). Leprosy HHCs with 0 BCG scar at time zero (t0) have a shorter survival time (average time of 22 months between t0 and outcome) when compared to those with 2 BCG scars (average time of 36 months between t0 and outcome). CONCLUSIONS: Vaccination of healthy individuals without signs and symptoms of leprosy is extremely important because BCG vaccine has an additional protective effect in those cases with 2 BCG scars throughout follow-up. Reducing the risk of leprosy HHCs becoming sick depends on preventive actions such as immunoprophylaxis and index cases treatment.
引用
- Gomes RR, Antunes DE, Dos Santos DF, et al. BCG vaccine and leprosy household contacts: Protective effect and probability to becoming sick during follow-up. Vaccine. 2019. PMID: 31500969. doi:10.1016/j.vaccine.2019.08.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。